Regeneron Pharmaceuticals Inc/ US75886F1075 /
30.08.2024 22:00:00 | Diff. +5,7600 | Volumen | Geld23:10:36 | Brief23:10:36 | Marktkapitalisierung | Dividendenr. | KGV |
---|---|---|---|---|---|---|---|
1.184,6900USD | +0,49% | 405.354 Umsatz: 250,7 Mio. |
1.175,0000Geld Vol: 100 | 1.193,2500Brief Vol: 100 | 130,59 Mrd.USD | - | 31,98 |
Aktiva
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Sachanlagen | 2.358,6050 | 2.575,8000 | 2.890,4000 | 3.221,6000 | 3.482,2000 | ||||||
Immaterielle Vermögensgegenstände | - | - | - | - | - | ||||||
Finanzanlagen | 1.486,4940 | 1.755 | 3.256,8000 | 3.135,6000 | 6.838 | ||||||
Anlagevermögen | 4.429,2560 | 5.286,9000 | 7.116,1000 | 7.384,2000 | 11.419,9000 | ||||||
Vorräte | 726,1380 | 1.151,2000 | 1.415,5000 | 1.916,6000 | 1.951,3000 | ||||||
Forderungen | 1.538,6420 | 1.723,7000 | 2.100 | 3.111,5000 | 6.036,5000 | ||||||
Liquide Mitteln | 812,7330 | 1.467,7000 | 1.617,8000 | 2.193,7000 | 2.885,6000 | ||||||
Umlaufvermögen | 4.335,0300 | 6.447,6000 | 7.689,1000 | 9.779,1000 | 14.014,9000 | ||||||
Aktiva, gesamt | 8.764,2860 | 11.734,5000 | 14.805,2000 | 17.163,3000 | 25.434,8000 |
Passiva
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Verbindlichkeiten aus Lieferungen und Leistungen | - | 218,2000 | 418,1000 | 475,5000 | 564 | ||||||
Langfristige Schulden | 703,4530 | 708,5000 | 713,9000 | 2.695,7000 | 1.980 | ||||||
Verbindlichkeiten gegenüber Kreditinstituten | - | - | - | - | - | ||||||
Rückstellungen | - | - | - | - | - | ||||||
Verbindlichkeiten | 2.620,2080 | 2.977,2000 | 3.715,5000 | 6.138 | 6.666 | ||||||
Gezeichnetes Kapital | ,1100 | ,1000 | ,1000 | ,1000 | ,1000 | ||||||
Eigenkapital | 6.144,0780 | 8.757,3000 | 11.089,7000 | 11.025,3000 | 18.768,8000 | ||||||
Minderheitenanteile | - | - | - | - | - | ||||||
Passiva, gesamt | 8.764,2860 | 11.734,5000 | 14.805,2000 | 17.163,3000 | 25.434,8000 |
Gewinn- und Verlustrechnung
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Umsatzerlöse | 5.872,2270 | 6.710,8000 | 7.863,4000 | 8.497,1000 | 16.071,7000 | ||||||
Abschreibungen (Gesamt) | - | - | - | - | - | ||||||
Betriebsergebnis | 2.079,5910 | 2.534,4000 | 2.209,8000 | 3.576,6000 | 8.946,8000 | ||||||
Zinsergebnis | -25,1190 | -28,2000 | -30,2000 | -56,9000 | -57,3000 | ||||||
Ergebnis vor Steuern | 2.078,5110 | 2.553,5000 | 2.429,1000 | 3.810,4000 | 9.325,8000 | ||||||
Ertragsteuern | -880 | -109,1000 | -313,3000 | 297,2000 | 1.250,5000 | ||||||
Gewinnanteil Minderheitsgesellschafter | - | - | - | - | - | ||||||
Konzernjahresüberschuss | 1.198,5110 | 2.444,4000 | 2.115,8000 | 3.513,2000 | 8.075,3000 |
Pro Aktie
Cash Flow
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow aus laufender Geschäftstätigkeit | 1.307,1120 | 2.195,1000 | 2.430 | 2.618,1000 | 7.081,3000 | ||||||
Cash Flow aus Investitionstätigkeit | -1.005,1820 | -1.463 | -2.027,8000 | -70,6000 | -5.384,7000 | ||||||
Cash Flow aus Finanzierungstätigkeit | -24,4000 | -77,1000 | -252,1000 | -1.970,5000 | -1.005,8000 | ||||||
Veränderung der liquiden Mittel | 277,5300 | 655 | 150,1000 | 577 | 690,8000 | ||||||
Anzahl der Mitarbeiter | 6.200 | 7.400 | 8.100 | 9.123 | 10.368 |